Valneva and Pfizer: new positive data on Lyme disease vaccine

Valneva and Pfizer have reported positive Phase 2 results for their Lyme disease vaccine candidate, VLA15. The VLA15-221 study demonstrated a strong immune response and a favorable safety profile following a second booster dose.

The data show an effective response for all six serotypes of the bacteria in children, adolescents and adults. A seroconversion of more than 90% was observed. These results are consistent with those of previous doses.

Currently, there is no vaccine for this growing disease. VLA15 remains the most advanced candidate with two Phase 3 trials underway. The CDC estimates 476,000 annual cases in the United States and 129,000 in Europe.